An anti-CD22 immunotoxin is a monoclonal antibody targeting CD22 linked to a cytotoxic agent. As of August 2009, it was studied in the treatment of some types of B-cell cancer. It binds to CD22, a receptor protein on the surface of normal B cells and B-cell tumors, and, upon internalization, kills the cells, acting as immunotoxin.

从cd22 car-t临床试验上能看出，cd22大多是作为扩大cd19 car t细胞治疗的补充（包括cd20），多靶点联合使它们能够靶向cd19（-）逃脱血液肿瘤，同时保留其前期功效。

2021年7月21日 · A novel anti-CD22 CAR with 41BB and CD3ζ costimulatory domains was developed and tested for safety in 21 pediatric and young adult patients with relapsed/refractory B-ALL, with 80% previously receiving CD19 targeted therapy. 45 Grade 1–2 cytokine release syndrome (CRS) occurred in 76% of patients.

Antibodies that detect CD22 can be used in several scientific applications, including Flow Cytometry, Immunohistochemistry, Western Blot, Immunocytochemistry and ELISA. These antibodies target CD22 in Human, Mouse, Rat, Canine and Non-human primate samples. Our CD22 monoclonal, recombinant monoclonal and polyclonal antibodies...

The anti-CD22 antibody Epratuzumab is in clinical trials for B-cell non-Hodgkin lymphoma and systemic lupus erythematosus, but shows a mostly unknown mode of action. We generated a new mouse model that expresses human CD22 instead of murine CD22 (Huki CD22 mice), in which human CD22 can be targeted.

2023年10月11日 · CD22 expression is independent of CD19 expression in malignant B cells. Consequently, CD22 is a potential alternative target for CD19 CAR-T cell-resistant patients. CD22-targeted therapies, mainly including the antibody–drug conjugates (ADCs) and CAR-T cells, have come into wide clinical use with acceptable toxicities and promising efficacy.

CD22 is a member of the B cell receptor family and is implicated in B cell function and development. It is expressed on multiple forms of B cell lymphoma and is an attractive cancer therapeutic target. We report here the identification of two fully human anti-CD22 antibodies using phage display methodology.

In the present study, we generated a recombinant anti-CD22 scFv–apoptin fusion protein as a bifunctional molecule: the anti-CD22 scFv moiety targets the CD22 antigen on malignant B-cells surface and apoptin specifically kills the tumor cells.

2021年7月2日 · Background: To observe efficacy of the anti-CD22 chimeric antigen receptor modified (anti-CD22-CAR) T cell salvage therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and B cell acute lymphoid leukemia (B-ALL) patients whose disease did not reach CR or progressed again after anti-CD19-CAR T cell therapy.

Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant lymphomas. Pinatuzumab vedotin is an anti-CD22 ADC and polatuzumab vedotin an anti-CD79B ADC that are both linked to t …